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During the past year, the Department of Radiation Oncology at IUPUI has been 
working with IUCF to develop an ability to use protons to treat cancer. We have made 
significant progress in several key areas. During three runs we have developed and tested 
a beam spreading system and range modulator. At the same time, in vivo and in vitro 
measurements of the beam relative biological effectiveness (RBE) were made. Finally, our 
initial successes and future plans have led to additional funding for the coming year. 
Proton radiation therapy has several advantages over other methods of cancer treat- 
ment. By using the proton Bragg peak to treat tumors, two advantages over 60Co treat- 
ments are readily apparent: 1) For a fixed dose at the tumor, the protons generally give a 
lower dose (and hence do less damage) to healthy tissue in front of the tumor, 2) the sharp 
cut-off of the Bragg peak ensures that healthy tissue beyond the tumor is not damaged by 
protons. The main disadvantage of proton radiation therapy is the cost/availability of a 
suitable energy (-- 200 MeV) proton beam. The beam splitting capability at IUCF allows 
us to develop a proton radiation therapy program while making only a minimd impact 
on the nuclear physics research program. As Cooler experiments become a larger fraction 
of the nuclear physics research, even more split beam should be available, as the Cooler 
typically uses less than 10% of the available beam. Before we can take advantage of that, 
an additional Lambertson magnet (L4) will need to be installed to allow splitting between 
the Cooler and the y-cave. 
The work on the proton therapy beam delivery system has focussed on three ar- 
eas: beam spreading, range modulation, and dose monitoring. In order to treat typical 
size tumors, the beam needs to be spread in a uniform intensity well beyond its typical 
2 mm diameter. The beam spreading system is a proton nozzle,' designed using a pro- 
gram called NEU (Nozzle with Everything A typical beam delivery geometry 
is shown in Fig. 1. Beam passes through a thick primary scattering foil and after some 
distance is shaped by two concentric annuli which are immediately followed by a second 
lsecond scatter) 
Figure 1. Schematic layout of beam line components. 
scattering foil. The foil thicknesses and annuli diameters depend on the field size, beam 
energy, and relative positions of the scattering foils and target. We have tested two beam 
spreading systems, which produced flat fields (3~5%) of 10 and 15 cm diameter. 
The 180-200 MeV proton beams frequently run at IUCF are particularly well suited 
for proton radiation therapy. The cyclotron's maximum energy of 200 MeV protons gives 
a reasonable range in tissue (N  24 cm in water). This is generally sufficient to reach most 
tumors. For tumors located closer to the surface, additional tissue-equivalent material is 
placed in front of the tumor to give the protons the correct depth. In order to deliver a 
uniform dose to tumors with a large extent in the longitudinal (beam) direction, we Rave 
manufactured range modulators of a rotating stepped design.3 By superimposing Bragg 
peaks which are shifted in position and varying in intensity, a reasonably flat longitudinal 
distribution can be obtained. The shift in the Bragg peak position is obtained by having 
plastic of appropriate thickness rotate into the beam. The intensity of the Bragg peak at 
that position is controlled by adjusting the length of time that thickness of plastic is in the 
beam. Fig. 2 shows a typical range modulator, which is rotated through the beam. We 
have written a computer program that determines the fraction of beam required at each 
range to give an integrated dose that is flat to better than f 2% over the spread out Bragg 
peak (SOBP). Thus far, we have tested range modulators designed to produce SOBP's of 
4, 8, and 18 cm. Results for the latter are shown in Fig. 3. 
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Figure 2. a) beam view of range modulator; b) side view of range modulator. 
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Figure 9. Unmodulated Bragg peak (dots) and SOBP (solid) for 18 cm range modulator. 
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In order to deliver accurate doses, reliable non-destructive beam diagnostics are nec- 
essary. Since typical beam currents (in our development mode) are on the order of 1 nA 
or less, normal electrostatic pick-ups are too insensitive. Instead, a secondary electron 
emission monitor (SEEM) is used in the proton therapy beam line. The SEEM consists 
of several layers of aluminized mylar, with alternate layers biased with a negative voltage 
and the remaining layers acting as electron collectors. The electron current is read on a 
current integrator. The SEEM does not affect the beam quality for proton therapy as the 
energy loss in the thin mylar is less than 1 MeV compared with N 15 MeV throughout 
the remainder of the beam spreading system. The SEEM is calibrated against a Faraday 
cup and an ion chamber so that integrated proton flux and the dose can be measured 
simultaneously. A pair of split ion chambers have been acquired and will also be used in 
the future. 
Finally, we have measured the relative biological effectiveness (RBE) of the beam 
produced in our delivery system. Fifteen cell cultures and 67 mice have been irradiated 
with 200 MeV protons in doses of 150, 400, and 800 cGy. The RBE has been evaluated 
using mouse LD 100, spleen cell cellularity, lymphocyte proliferation, and frequency of 
chromatin fragment formation as indicators. Our preliminary results give an RBE value 
(compared to 60Co) of 1.24 f 0.12. 
Our success thus far has led to a commitment of funds from the Lion's Club of Indiana. 
They will donate $300,000 for the development of the proton therapy facility to the point 
where first patient treatments can be done. While there remains a considerable amount of 
work to be done, we project that the first patient will be treated as early as June of 1992. 
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